We conclude that in severe glaucoma attacks, (1) a single administration of AAV2-BDNF is sufficient for significant RGCs neuroprotection, and (2) for glaucoma therapy, the careful control of BDNF concentration is the main factor securing the long-term responsiveness of RGCs and the maintenance of TrkB normal levels. Here, BDNF is linked to glaucoma.